About us
Services & Solutions
Chemistry DMPK Discovery Biology Oncology Pharmacology Biologics
Medicinal Chemistry Computational Chemistry Synthetic Chemistry Analytical Chemistry Scale Up Chemistry
In Vivo PK and TK In Vitro ADME Bioanalytical Service Exploratory Toxicity In Rodents, Dogs and Monkeys Large Molecules Capabilities Bioanalytical Instruments
Biochemical Assays Cellular Assays Protein Science Assay Technologies Biophysics SPR Safety Pharmacology Screening Services Key Instruments
PDX CDX Orthotopic Models Syngeneic Models Humanized Mouse Models CAR-T and CAR-NK Mouse Models In Vitro Assays
Immunology Inflammation Metabolic NASH Respiratory Neuroscience
Systematic Antibody Discovery Service
Process R&D Scale Up Synthesis DS Manufacturing
Flow Chemistry Sugar Chemistry Peptide Chemistry Preparative Purification Capacity Process Safety Assessment
Synthetic and Scale Up Chemistry Parallel Synthesis
Flow Chemistry Kilo and Pilot Scale Production RSM and Intermediates Manufacturing QA EHS
Pre-Formulation Formulation, Analytical and Process Development Drug Product Manufacturing
Bioavailability Enhancement Modified Release
Commercial Manufacturing
Platforms
News & Resources
Careers
Contact us
CN EN
×
news
Company News Events Insights Webinars Virtual Tours
Congratulations to NanoRay Biotech for its anticancer therapy approved by the US FDA for Clinical Trial
Shanghai, September 29, 2022 – Congratulations to NanoRay Biotech Co., Ltd.’s [Auger Molecular Therapy], which has been approved by the US FDA for Clinical Trial.
September 29, 2022
BioDuro-Sundia and X-Chem enter partnership to launch DEL services in China for the discovery of new small molecule drugs
Shanghai, August 8, 2022 – BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International
August 08, 2022
Bioduro-Sundia’s Wuxi GMP Manufacturing Facility Granted the Drug Manufacturing License
Shanghai, July 1st, 2022 – BioDuro-Sundia, a leading drug discovery, development and commercial services organization backed by Advent International
July 01, 2022
BioDuro-Sundia Appoints Kent Payne CEO
San Diego, February 14, 2022 – BioDuro-Sundia, a leading drug discovery, development and commercial services organization backed by Advent International, announced today the appointment of Kent M. Payne, PhD, as Chief Executive Officer. He originally joined BioDuro-Sundia in 2019 as President, Global CMC Solutions.
February 14, 2022
Congratulations to Dr. Junbo Wang & his team for winning the Best Collaboration Award of Luye Pharma in 2021
Shanghai, January 20, 2022 – Dr. Junbo Wang & his team from BioDuro-Sundia’s Chemistry department won the ” Best Collaboration Award ” issued by Luye Pharma, in recognition of their great contribution for drug chemistry discovery projects in 2021.
January 20, 2022
Total 84 12345678...1617
NASH Webinar Coming Soon
Register Today! This online event "Unleashing Innovation: A New Obesogenic NASH Model with High Clinically Translational Power" translates NASH/NAFLD research to clinic with better representative data, faster.
View more
Subscribe to BioDuro-Sundia
Receive our newsletter and information on upcoming events
Your trusted partner from drug discovery and
development to commercialization

Home

About us

Services & Solutions

Platforms

News & Resources

Careers

Contact us

Explore

Discovery

Drug Substance

Drug Product

© 2023 BioDuro-Sundia. All rights reserved
Terms of Use Privacy Policy
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all